Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC1A2 antisense RNA 2 (SLC1A2-AS2), also known as AC090625.2, is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the SLC1A2 gene region on chromosome 11. Antisense RNAs are non-protein-coding transcripts that may regulate expression of adjacent or overlapping protein-coding genes through transcriptional interference, RNA-RNA base pairing, or epigenetic mechanisms[6]. SLC1A2-AS2 is part of the growing group of lncRNAs annotated in the human genome, but there are no published functional data, molecular pathway assignments, or disease associations specifically describing the role of SLC1A2-AS2 as of September 2025. It is not currently classified as a therapeutic target, nor are there known drugs, mechanisms, or biomarkers involving this RNA. No substantial errors or misspellings are present in the supplied target name; the entry refers to a probable, though little-studied, human non-coding RNA gene.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC1A2 antisense RNA 2 (SLC1A2-AS2).